Merlin CP-GEP becomes first NCCN-endorsed molecular test for early-stage melanoma risk assessment
NCCN guidelines now recommend Merlin CP-GEP for early-stage melanoma risk assessment. Discover what this changes for clinicians and diagnostics adoption.